| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥183.4B | ¥169.7B | +8.1% |
| Operating Income | ¥22.8B | ¥26.7B | -14.6% |
| Ordinary Income | ¥24.2B | ¥28.6B | -15.2% |
| Net Income | ¥16.9B | ¥20.8B | -19.1% |
| ROE | 6.8% | 8.2% | - |
FY2025 Q3 cumulative results show revenue of 183.4 billion yen (YoY +8.1%), operating income of 22.8 billion yen (YoY -14.6%), ordinary income of 24.2 billion yen (YoY -15.2%), and net income of 16.9 billion yen (YoY -19.1%). The company achieved top-line growth driven primarily by the Water Healthcare business, but profitability deteriorated significantly with operating margin contracting from 15.7% to 12.4%, representing a 331 basis point decline. Gross profit margin remained stable at 68.2%, indicating the profit pressure originated from elevated SG&A expenses which increased to 55.7% of revenue. The gap between revenue growth of 8.1% and operating income decline of 14.6% reflects a revenue-up-profit-down pattern, suggesting structural cost challenges despite market expansion. Non-operating income contributed positively with gains on investment securities sales of 1.5 billion yen, partially offsetting the operating weakness. Balance sheet strength remains intact with cash and deposits of 139.3 billion yen and equity ratio of 71.1%, though working capital efficiency deteriorated notably with DSO extending to 139 days and inventory days reaching 101 days.
Revenue increased 13.8 billion yen year-over-year to 183.4 billion yen, representing 8.1% growth. The Water Healthcare segment, comprising the core business, generated revenue of 160.3 billion yen with year-over-year growth of 12.2 billion yen (8.2% increase). The Medical Related segment contributed 23.2 billion yen in revenue, up 1.6 billion yen (7.4% increase) from the prior year. The revenue expansion was broad-based across both segments, though the Water Healthcare business remains the primary growth driver accounting for 87.4% of total sales.
Operating income declined 3.9 billion yen to 22.8 billion yen despite the revenue growth. The Water Healthcare segment generated operating income of 20.8 billion yen, down 2.8 billion yen (12.0% decline) year-over-year, with segment margin contracting from 16.0% to 13.0%. The Medical Related segment produced operating income of 2.0 billion yen, declining 1.1 billion yen (34.5% decrease) from the prior year, with margin falling from 14.3% to 8.7%. The profit contraction across both segments indicates systematic cost pressure rather than isolated segment issues. SG&A expenses reached 102.3 billion yen, representing 55.7% of revenue compared to an implied lower ratio in the prior period when operating margin was 15.7%. This suggests SG&A growth outpaced revenue growth, likely driven by increased sales and marketing expenses or administrative costs associated with business expansion.
Ordinary income of 24.2 billion yen exceeded operating income by 1.4 billion yen, primarily due to gains on sales of investment securities of 1.5 billion yen and gains on sales of non-current assets of 0.3 billion yen. These non-recurring factors partially cushioned the operating profit decline. The differential between ordinary income (24.2 billion yen) and net income (16.9 billion yen) of 7.3 billion yen, representing a 30.2% reduction, reflects the tax burden with profit before tax of 24.2 billion yen and tax expense of approximately 7.3 billion yen, yielding an effective tax rate near 30.2%. No material extraordinary losses or one-time charges below the ordinary income line were evident in the data provided.
The performance pattern is characterized as revenue-up-profit-down, driven by top-line momentum across both business segments offset by margin compression from elevated operating expenses and proportionally higher cost structure. The 331 basis point operating margin contraction represents the central profitability challenge requiring management attention on expense control and operating leverage recovery.
The Water Healthcare segment represents the core business, generating 160.3 billion yen in revenue (87.4% of total) and 20.8 billion yen in operating income. Revenue grew 8.2% year-over-year while operating income declined 12.0%, resulting in segment operating margin of 13.0%, down from 16.0% in the prior year. This 300 basis point margin contraction in the primary revenue driver indicates systematic profitability pressure in the core water purifier and related business operations. The segment remains highly profitable in absolute terms but faces headwinds from cost inflation or competitive pricing dynamics.
The Medical Related segment contributed 23.2 billion yen in revenue (12.7% of total) and 2.0 billion yen in operating income. Revenue increased 7.4% year-over-year but operating income fell sharply by 34.5%, compressing segment margin to 8.7% from 14.3%. The 560 basis point margin decline in this smaller segment was more severe than the core business, suggesting either investment phase costs in medical/regenerative medicine fields or business model challenges in scaling profitability. The Medical Related segment operates at a lower absolute margin than Water Healthcare (8.7% versus 13.0%), though both segments experienced margin pressure during the period.
The profitability divergence between segments is notable: the Water Healthcare business maintains higher margins despite its maturity, while the Medical Related business shows lower margins consistent with early-stage healthcare ventures requiring upfront investment. Both segments face profit headwinds despite revenue growth, indicating company-wide operating expense challenges rather than isolated segment issues.
[Profitability] ROE of 6.8% declined from the prior period level, with operating margin of 12.4% contracting 331 basis points from 15.7% year-over-year. Net profit margin fell to 9.2% from 12.3%, representing a 310 basis point deterioration driven by both operating margin compression and proportionally higher tax burden. Gross profit margin remained stable at 68.2%, indicating cost of sales control was maintained while SG&A expenses expanded disproportionately to 55.7% of revenue. The profitability decline stems primarily from operating expense deleverage rather than gross margin erosion. [Cash Quality] Cash and deposits of 139.3 billion yen provide substantial liquidity, covering short-term debt and current liabilities with a ratio of 1.91 times. Investment securities increased to 23.7 billion yen, up 81.7% year-over-year, reflecting enhanced financial asset allocation. Total liquid resources (cash plus marketable securities) of 163.0 billion yen represent 46.7% of total assets, indicating conservative balance sheet positioning. [Investment Efficiency] Asset turnover of 0.53 reflects moderate capital intensity, with total assets of 349.0 billion yen supporting annualized revenue generation. Working capital efficiency deteriorated significantly with receivables turnover extending to 139 days, inventory turnover reaching 101 days, and cash conversion cycle elongating to 199 days, all substantially above healthy benchmark ranges. The working capital deterioration absorbed cash and reduced operational efficiency. [Financial Health] Equity ratio of 71.1% indicates strong capitalization, with total equity of 248.2 billion yen supporting total assets of 349.0 billion yen. Current ratio of 312.9% provides substantial liquidity buffer, with current assets of 227.7 billion yen covering current liabilities of 72.8 billion yen by 3.1 times. Long-term loans of 10.5 billion yen represent minimal leverage, with debt-to-equity ratio of 0.04 indicating conservative financial structure. Interest coverage is extremely high at approximately 583 times based on operating income relative to negligible interest expense, confirming no financial distress risk from debt burden.
Cash and deposits increased to 139.3 billion yen, though annual comparison context is limited in quarterly data. The substantial cash position relative to operating scale (76% of Q3 cumulative revenue) indicates strong liquidity management and cash generation historically. Working capital movements reveal efficiency deterioration: accounts receivable reached 70.0 billion yen, representing 139 days of sales outstanding and suggesting extended collection periods or customer credit term expansion. Inventories totaled 13.8 billion yen with turnover of 101 days, elevated compared to manufacturing sector norms and indicating potential overstocking or slower product rotation. Trade payables of 21.2 billion yen provide 41 days of payment deferral, yielding a cash conversion cycle of 199 days that significantly exceeds optimal working capital efficiency. The extended working capital cycle implies approximately 16.6 months of operating cycle from cash outlay to collection, absorbing substantial capital that could otherwise support growth or shareholder returns. Investment securities increased 10.1 billion yen to 23.7 billion yen year-over-year, reflecting allocation of surplus cash to financial assets, likely including strategic holdings or yield-seeking investments. Treasury stock holdings expanded, indicating share repurchase activity that deployed capital for shareholder returns alongside dividend policy. The balance sheet composition suggests internally generated cash flow has been allocated across three channels: working capital absorption from business expansion, financial asset accumulation, and equity capital return through buybacks. Short-term liquidity remains robust with current assets covering current liabilities 3.1 times, ensuring adequate buffer for operational needs and strategic flexibility. The cash coverage ratio of 1.91 times for near-term obligations confirms no liquidity stress despite working capital inefficiency.
Ordinary income of 24.2 billion yen versus operating income of 22.8 billion yen reflects net non-operating contribution of 1.4 billion yen. This comprises gains on sales of investment securities of 1.5 billion yen and gains on disposal of non-current assets of 0.3 billion yen as primary components, partially offset by financial costs. Non-operating income represents 0.8% of revenue, consisting of investment-related gains that are episodic in nature rather than recurring operational earnings. The presence of 1.5 billion yen in securities sale gains introduces non-recurring elements to reported profitability, accounting for approximately 6.2% of ordinary income and 8.9% of net income, suggesting core operating earnings quality is softer than headline figures indicate. Operating cash flow data is not provided in the quarterly disclosure, preventing direct comparison between reported net income and cash generation to assess accrual quality. The expansion of working capital, evidenced by extended receivables (139 DSO) and elevated inventory (101 DIO), suggests potential accrual buildup where revenue recognition may be outpacing cash collection. This working capital deterioration pattern typically correlates with weaker earnings quality as profits increasingly rely on credit sales and inventory build rather than realized cash flows. The effective tax rate of approximately 30% applied to profit before tax appears consistent with standard corporate taxation, with no indication of unusual tax benefits or charges affecting earnings quality from tax items. Overall earnings quality shows mixed signals: stable gross margins and core business revenue growth support operational legitimacy, but margin compression, reliance on non-recurring gains, and working capital deterioration introduce quality concerns warranting monitoring in subsequent periods.
Full-year guidance projects revenue of 250.0 billion yen, operating income of 35.4 billion yen, ordinary income of 37.0 billion yen, and net income of 23.1 billion yen (calculated from EPS forecast of 304.74 yen times average shares). Q3 cumulative progress rates are: revenue 73.4%, operating income 64.4%, ordinary income 65.4%, and net income 73.2%. Revenue progress of 73.4% at the nine-month mark slightly lags the standard 75% expectation, indicating fourth quarter revenue must reach 66.6 billion yen to achieve guidance, representing 21.5% sequential growth from the Q3 run rate. Operating income progress of 64.4% shows more significant shortfall against the 75% benchmark, requiring Q4 operating income of 12.6 billion yen, which would represent 55% sequential increase from the Q3 quarterly rate and margin recovery from current 12.4% to approximately 18.9% to meet full-year targets. This implies substantial fourth quarter margin improvement is embedded in guidance, likely dependent on cost control initiatives, favorable business mix, or seasonal strength in the Water Healthcare business. The ordinary income and net income progress rates similarly trail standard pace, with Q4 requiring disproportionate profit contribution. Given the year-to-date pattern of margin compression and working capital deterioration, achieving the full-year operating income target of 35.4 billion yen represents meaningful execution risk unless structural cost improvements or revenue acceleration materialize in the final quarter. No specific forecast assumptions or revision commentary was provided in the disclosed data, though the gap between Q3 run-rate profitability and implied Q4 requirements suggests either conservative initial guidance or anticipated business inflection. Order backlog data is not disclosed, limiting visibility into contracted forward revenue. The guidance implies full-year revenue growth of 11.3% and operating income growth of 7.7%, reflecting an improving but still compressed operating margin trajectory compared to historical levels.
Annual dividend forecast is 130.00 yen per share for the full fiscal year, paid as a year-end dividend with no interim distribution. Based on the net income forecast of 23.1 billion yen (EPS of 304.74 yen) and average outstanding shares of approximately 75.65 million shares, the implied dividend payout ratio is 42.7% (130.00 yen dividend divided by 304.74 yen forecast EPS). However, based on the Q3 cumulative net income of 16.9 billion yen and actual EPS of 206.29 yen, the current run-rate payout ratio would be 63.0%, reflecting the profit shortfall relative to full-year guidance. The 130.00 yen dividend represents year-over-year comparison context that was not explicitly provided in the data, though the dividend policy maintains a substantial cash return commitment. Share buyback activity is evidenced by increased treasury stock holdings, with treasury shares totaling 1,225 thousand shares. The specific buyback expenditure for the current period was not quantified in the provided data, limiting calculation of total return ratio combining dividends and repurchases. The company's capital allocation reflects balanced approach between dividends and opportunistic share repurchases, supported by substantial cash reserves of 139.3 billion yen and minimal debt burden. Dividend sustainability appears adequate given the cash position and equity base of 248.2 billion yen, though the elevated run-rate payout ratio of 63% against depressed nine-month earnings suggests some sensitivity to profit recovery for maintaining current dividend levels. Total shareholder return policy demonstrates commitment to capital return with approximately 9.8 billion yen in forecast dividend payments (130 yen times 75.65 million average shares) representing meaningful cash distribution alongside the share buyback program.
Operating margin compression risk: Operating margin contracted 331 basis points to 12.4% in Q3 from 15.7% in the prior year, driven by SG&A expense growth outpacing revenue growth. SG&A expenses reached 102.3 billion yen, representing 55.7% of revenue and absorbing a disproportionate share of gross profit. If cost inflation, competitive pricing pressure, or business expansion investments continue without operating leverage recovery, profitability could deteriorate further. The company requires approximately 12.6 billion yen in Q4 operating income (18.9% margin) to achieve full-year guidance, substantially above the Q3 run-rate, creating execution risk.
Working capital deterioration risk: Days sales outstanding extended to 139 days, days inventory outstanding reached 101 days, and cash conversion cycle elongated to 199 days, all significantly exceeding healthy operational benchmarks. The extended working capital cycle absorbs approximately 109.2 billion yen in operating assets (receivables plus inventory less payables), representing 31% of total assets and 44% of equity. Further working capital expansion would impair cash generation, reduce returns on invested capital, and constrain financial flexibility. Elevated receivables raise collection risk and potential bad debt exposure, while extended inventory levels increase obsolescence and carrying cost risks.
Growth sustainability and profitability trade-off risk: Revenue growth of 8.1% in Q3 accompanied by operating income decline of 14.6% demonstrates negative operating leverage, where incremental revenue generates below-average or negative incremental profit. This pattern suggests either pricing concessions to drive volume growth, higher customer acquisition costs, or product mix shift toward lower-margin offerings. If the company cannot restore positive operating leverage, continued revenue expansion may further erode shareholder value through declining returns on capital. The Medical Related segment margin compression to 8.7% from 14.3% illustrates particular profitability pressure in growth initiatives outside the core Water Healthcare business.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE of 6.8% exceeds the manufacturing industry median of 5.8% for 2025-Q3, positioning the company in the upper half of peer performance despite year-over-year deterioration. Operating margin of 12.4% also exceeds the industry median of 8.9%, indicating above-average operational profitability relative to manufacturing sector comparables. Net profit margin of 9.2% substantially exceeds the industry median of 6.5%, confirming the company maintains pricing power or cost efficiency advantages in its markets despite recent margin pressure.
Financial Health: Equity ratio of 71.1% significantly exceeds the industry median of 63.8%, reflecting conservative capitalization and lower financial leverage than typical manufacturing peers. Current ratio of 312.9% far exceeds the industry median of 2.87x, indicating substantially stronger liquidity positioning. The minimal debt burden with interest-bearing debt of only 10.5 billion yen and net cash position (net debt/EBITDA of negative) contrasts favorably with the industry median net debt/EBITDA of negative 1.11, confirming balance sheet strength relative to sector.
Efficiency: Asset turnover of 0.53 falls below the industry median of 0.56, suggesting slightly lower capital efficiency in generating revenue per yen of assets deployed. Working capital turnover deterioration is evident with operating working capital days substantially exceeding industry benchmarks: receivables turnover of 139 days far exceeds the median of 85 days, inventory turnover of 101 days approximates the median of 112 days, and cash conversion cycle of 199 days substantially exceeds the industry median of 111 days. The working capital efficiency gap represents a material relative weakness requiring management focus.
Growth: Revenue growth of 8.1% year-over-year exceeds the industry median growth of 2.8%, confirming above-average top-line momentum. However, EPS growth of negative 15.1% (206.29 yen versus 243.02 yen prior year) underperforms the industry median EPS growth of 9%, reflecting the profit margin compression challenge. The divergence between revenue outperformance and earnings underperformance relative to peers highlights the company-specific cost structure issues.
※ Industry: Manufacturing (105 companies), Comparison: 2025-Q3 fiscal periods, Source: Proprietary analysis
Profitability inflection required for value realization: The company demonstrates revenue growth momentum exceeding manufacturing sector peers at 8.1% versus median 2.8%, but operating margin compression of 331 basis points to 12.4% and net income decline of 19.1% indicate negative operating leverage that must be reversed. Management must demonstrate cost control and operating efficiency recovery in Q4 and subsequent periods to justify current valuation multiples. The gap between Q3 profitability run-rate and full-year guidance implies expectation of meaningful Q4 margin improvement, creating a near-term catalyst for performance validation or disappointment.
Balance sheet strength provides strategic flexibility and downside protection: Equity ratio of 71.1%, net cash position with 139.3 billion yen in cash against 10.5 billion yen in long-term debt, and current ratio of 312.9% position the company among the strongest balance sheets in the manufacturing sector. This financial strength enables continued dividend payments (130 yen annual dividend with 42.7% payout ratio on forecast earnings), share repurchases, and potential strategic investments without financial distress risk. However, working capital inefficiency with 199-day cash conversion cycle absorbs substantial capital and reduces effective returns, representing an operational improvement opportunity that could unlock significant cash flow if addressed.
Working capital optimization represents material earnings quality and cash flow upside: Days sales outstanding of 139 days versus industry median of 85 days and the resulting 199-day cash conversion cycle indicate approximately 54 days of excess working capital relative to sector norms. Normalizing working capital to industry-median efficiency could release an estimated 27 billion yen in cash (54 days times approximately 500 million yen daily revenue run-rate), representing 19% of current equity value. Management focus on receivables collection acceleration and inventory optimization would simultaneously improve cash flow generation and return on invested capital, potentially re-rating the equity multiple if sustained improvements are demonstrated.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.